Our present study suggests that the acquisition of the NK1.1 cell surface marker by dnTGFβRII-CD8 T cells resulted in a highly pathogenic population that leads to development of T cell lymphoma with an aggressive clinical course. The gene discussed is CD8A; the disease is T-cell non-Hodgkin lymphoma.